IRWD

AI Memo

Ironwood

As of 2026-08-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

STARS-2 Phase 3 recruitment execution • 2026-11-15

Base target: $4 / p=50% prob

Biggest risk

The near-term positive print may already be substantially priced in, while the stock remains exposed to LINZESS execution, limited forward clinical visibility, and uncertainty around STARS-2 and apraglutide commercialization. Verified post-print analyst revisions and market-reaction attribution are unavailable.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

Strong LINZESS pricing and prescription growth, raised 2026 guidance, positive Q2 profitability, and repayment of $200 million in convertible notes support cash-flow and balance-sheet improvement. STARS-2 provides longer-term optionality.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-25

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

LINZESS execution and raised 2026 guidance
Apraglutide diversification potential
Strong LINZESS pricing and prescription growth, raised 2026 guidance, positive Q2 profitability, and repayment of $200 million in convertible notes support cash-flow and balance-sheet improvement.

BearKey bullets

LINZESS remains the principal commercial driver, creating concentration and execution risk.
Peer comparisons are loose because the candidate set mixes commercial biopharma and clinical-stage companies.
Post-earnings analyst revisions, consensus-surprise detail, and verified market-reaction attribution are unavailable.

WatchKey bullets

STARS-2 Phase 3 recruitment execution

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $4 (p=50%)

Target spread vs base: +16% / -30%

Scenario probabilities

Bull Target: $5 (p=25%)Base Target: $4 (p=50%)Bear Target: $3 (p=25%)

Commentary

News tone is favorable following strong Q2 results, raised guidance, LINZESS growth, debt repayment, and STARS-2 recruitment. Social coverage, options data, short interest, employee sentiment, and verified post-print market reaction are unavailable; the positive news tone should not be treated as confirmation of a durable rerating.

As of 2026-08-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

LINZESS execution and raised 2026 guidance
Apraglutide diversification potential

Scenarios

Bull Target (Scenario probability)

$5 / p=25% prob

Base Target (Scenario probability)

$4 / p=50% prob

Bear Target (Scenario probability)

$3 / p=25% prob

Analysis 2026-08-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-15
STARS-2 Phase 3 recruitment execution
The confirmatory Phase 3 STARS-2 trial of apraglutide in short bowel syndrome with intestinal failure is actively recruiting. Enrollment progress and development execution are the clearest forward monitors, but timing for interim milestones was not disclosed. [#SEC-8K-2026-08-06]
Prob 60.00% • Move 12.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

LINZESS execution and raised 2026 guidance
2026-11-15
Q2 U.S. LINZESS net sales were $282 million and year-to-date sales were $555 million, up 44% year over year. Ironwood raised full-year LINZESS, total revenue, and adjusted EBITDA guidance. Improved net pricing and mid-single-digit prescription-demand growth support the near-term case, although much of the update may be reflected in the stock. [#SEC-8K-2026-08-06]
Prob 80% • Move 8% • Priced-in 75%

Long-term Catalysts

Months to a year

Apraglutide diversification potential
2027-08-17
Successful STARS-2 execution and subsequent regulatory progress could create a second commercial growth driver, but clinical, regulatory, and commercialization outcomes remain unproven. [#SEC-8K-2026-08-06]
Prob 40% • Move 25% • Priced-in 30%

Risks

LINZESS remains the principal commercial driver, creating concentration and execution risk.
Peer comparisons are loose because the candidate set mixes commercial biopharma and clinical-stage companies.
Post-earnings analyst revisions, consensus-surprise detail, and verified market-reaction attribution are unavailable.
Raised 2026 guidance could be reset if pricing, prescription demand, or operating performance weakens.
STARS-2 enrollment, clinical outcomes, regulatory progress, and timing remain uncertain.

Peers

Symbol	Summary
EVO	Similar-sized biopharma candidate from the same sector, but its operating model and pipeline exposure are not directly comparable to LINZESS and apraglutide.
ALLO	Similar-market-cap biopharma candidate, but its clinical focus and commercial profile provide only loose comparison value.
AMGN	Large commercial biopharma comparator useful for sector context, but not a close operating or valuation peer for IRWD.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-25

Loading AI feed…

Symbol

Summary

EVO

Similar-sized biopharma candidate from the same sector, but its operating model and pipeline exposure are not directly comparable to LINZESS and apraglutide.

ALLO

Similar-market-cap biopharma candidate, but its clinical focus and commercial profile provide only loose comparison value.

AMGN

Large commercial biopharma comparator useful for sector context, but not a close operating or valuation peer for IRWD.